What is the recommended Matrixyl 3000 dosage?

Matrixyl 3000 dosing varies by experience level. Beginners typically start at 2mg daily, moderate users at 5mg 2x daily, and aggressive protocols use 10mg 2x daily.

How do you reconstitute Matrixyl 3000?

Matrixyl 3000 comes as a pre-filled device — no reconstitution needed.

What is the half-life of Matrixyl 3000?

The half-life of Matrixyl 3000 is ~6 hours (topical; no systemic PK data). This determines how frequently you need to dose for consistent blood levels.

Matrixyl 3000

Q: What are the side effects of Matrixyl 3000?

Generally well-tolerated as a topical cosmeceutical. Clinical studies and the CIR safety assessment report no significant adverse effects at typical use concentrations (<10 ppm). Rare cases of mild temporary redness, tingling, or irritation at the application site may occur, particularly in individuals with sensitive skin. No systemic side effects expected due to minimal transdermal absorption. Allergic contact dermatitis is theoretically possible but has not been reported at significant rates.

Anti-AgingTopicalResearchGrade A~6 hours (topical; no systemic PK data) half-life

Anti-WrinkleCollagen BoosterAnti-InflammatoryTopical PeptideCosmeceuticalMatrikineDual-Peptide Complex16 weeks on / 2 weeks off

Benefits

Dual-mechanism approach: collagen stimulation plus anti-inflammatory action

Stimulates synthesis of collagen types I, III, IV, and VII in dermal fibroblasts

Reduces IL-6 secretion to combat inflammaging-driven collagen breakdown

Clinical evidence of up to 45% reduction in deep wrinkle surface area in 2 months

Increases glycosaminoglycan production by up to 287% for improved skin hydration

Promotes fibronectin and elastin expression for enhanced skin elasticity

Well-tolerated topical with CIR Expert Panel safety confirmation

Compatible with retinoids, vitamin C, hyaluronic acid, and other anti-aging actives

Half-Life

~6 hours

Route

Topical

Frequency

Daily

Vial Sizes

5mg, 10mg

BAC Water

Pre-filled

Safety Grade

Grade A

Open Matrixyl 3000 Dosage Calculator

Calculate exact syringe units for your vial and dose

About Matrixyl 3000

Matrixyl 3000 is a patented dual-peptide complex developed by Sederma that combines Palmitoyl Tripeptide-1 (Pal-GHK, MW 578.8 Da) and Palmitoyl Tetrapeptide-7 (Pal-GQPR, MW 694.9 Da) to address skin aging through two complementary mechanisms. Palmitoyl Tripeptide-1 is a lipidated derivative of the GHK fragment found in type I collagen — the same tripeptide backbone as GHK-Cu but conjugated to palmitic acid instead of copper. It functions as a matrikine signaling molecule that activates fibroblast matrix receptors, upregulating synthesis of collagen types I, III, IV, and VII, as well as fibronectin and glycosaminoglycans including hyaluronic acid. Palmitoyl Tetrapeptide-7 is derived from a fragment of immunoglobulin G and targets the inflammatory component of skin aging by inhibiting interleukin-6 (IL-6) secretion from keratinocytes, reducing chronic low-grade inflammation (inflammaging) that accelerates collagen degradation. Both peptides are N-acylated with a 16-carbon palmitic acid chain to enhance lipophilicity and penetration through the stratum corneum. In manufacturer-sponsored double-blind clinical trials, twice-daily application of 3% Matrixyl 3000 cream for 2 months reduced the surface area occupied by deep wrinkles by 45%, increased skin tonicity by nearly 20%, and decreased wrinkle volume by 17.1% in male subjects. A six-month study reported up to 68% reduction in deep wrinkle surface area and 46% decrease in wrinkle density. In vitro, the combination stimulated collagen I production by 117%, collagen IV by 327%, and glycosaminoglycan synthesis by 287% compared to controls. A 2024 clinical trial of an eye cream containing palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 showed a 54.99% increase in collagen production and 18.81% improvement in elasticity over 12 weeks, with mRNA upregulation of Col I (1.8x), Col III (2.5x), Col IV (2.8x), elastin (5.0x), and fibronectin (1.6x). The Cosmetic Ingredient Review (CIR) Expert Panel assessed tripeptide-1, its fatty acyl derivatives, and palmitoyl tetrapeptide-7 as safe for use in cosmetics at current concentrations (typically <10 ppm for individual peptides). Matrixyl 3000 is not FDA-approved for any medical indication and remains a cosmeceutical ingredient with strong in vitro data and moderate clinical evidence from manufacturer-sponsored and independent trials.

Who Should Consider Matrixyl 3000

Adults over 30 seeking to reduce wrinkles and fine lines without injections
Individuals with photoaged skin looking for collagen-stimulating topical treatments
People concerned with inflammaging and chronic low-grade skin inflammation
Skincare enthusiasts building multi-peptide anti-aging regimens
Those seeking an upgrade from single-peptide Matrixyl (Pal-KTTKS) formulations
Individuals wanting a well-tolerated, non-irritating anti-aging active

How Matrixyl 3000 Works

Matrixyl 3000 combines two complementary matrikine signaling pathways. Palmitoyl Tripeptide-1 (Pal-GHK) is a lipidated fragment of type I collagen that mimics collagen breakdown products. When it reaches dermal fibroblasts, it engages cell-surface integrins and activates TGF-beta receptor-mediated signaling cascades, triggering transcriptional upregulation of collagen I, III, IV, and VII genes, as well as fibronectin and glycosaminoglycan synthesis. This is a feedback mechanism — collagen fragment detection signals the cell to produce replacement matrix. Palmitoyl Tetrapeptide-7 (Pal-GQPR) is derived from an immunoglobulin G fragment and targets a separate pathway: it inhibits interleukin-6 (IL-6) release from UVB-stimulated keratinocytes and reduces NF-kB-mediated inflammatory signaling. Chronic low-grade skin inflammation (inflammaging) drives MMP expression and accelerates collagen degradation, so by suppressing IL-6, Pal-GQPR protects existing collagen while Pal-GHK stimulates new production. Both peptides are conjugated to a 16-carbon palmitic acid chain at their N-terminus, dramatically increasing lipophilicity and enabling penetration through the hydrophobic stratum corneum to reach target cells in the dermis. The combination of collagen synthesis stimulation and inflammatory pathway inhibition produces greater anti-wrinkle efficacy than either peptide alone.

What to Expect

Week 1-2

No visible anti-aging changes expected. The peptide complex begins accumulating in the upper skin layers. Some users report an immediate smoothing or hydrating sensation from the serum vehicle itself.

Weeks 2-4

Early improvements in skin texture and hydration may become noticeable. Pal-GHK is activating fibroblast collagen synthesis while Pal-GQPR begins reducing inflammatory mediators. Fine surface lines may start to soften.

Weeks 4-8

Measurable wrinkle reduction becomes apparent. Manufacturer clinical data shows significant improvement by the 2-month mark, with up to 45% reduction in deep wrinkle surface area. Skin firmness and elasticity begin to improve as new collagen fibers mature.

Weeks 8-16

Continued progressive improvement. Collagen remodeling deepens. Wrinkle density decreases further. The 6-month Sederma study reported up to 68% wrinkle surface area reduction and 46% decrease in wrinkle density at the extended timepoint.

Week 16+

Maintenance phase. Continued application sustains and slowly builds on results. Effects are cumulative and ongoing. If discontinued, wrinkle depth and skin texture gradually return toward baseline over 6-12 weeks.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	2mg	Daily
Moderate	5mg	2x Daily
Aggressive	10mg	2x Daily

Note: Topical anti-aging peptide complex developed by Sederma (patent WO 2005/048968). Contains two matrikine peptides: Palmitoyl Tripeptide-1 (Pal-GHK) and Palmitoyl Tetrapeptide-7 (Pal-GQPR). Distinct from the original Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) — Matrixyl 3000 uses a dual-peptide approach combining collagen stimulation with anti-inflammatory action. Typical serum concentrations range from 3-8% of the Matrixyl 3000 complex. Dosing tiers above reflect approximate mg of combined active peptides per topical application. Apply to clean, dry skin targeting periorbital wrinkles, forehead lines, and nasolabial folds.

How to Inject Matrixyl 3000

Apply a thin layer of Matrixyl 3000 serum (3-8% complex concentration) to clean, dry skin on target areas — periorbital region, forehead, nasolabial folds, and neck. Use morning and evening before moisturizer. Allow 2-3 minutes for absorption before layering other products. Compatible with retinoids, vitamin C serums, hyaluronic acid, and niacinamide. Avoid applying immediately after strong chemical exfoliants (AHAs/BHAs at peel-strength concentrations) as compromised barrier may alter absorption. For enhanced results, can be combined with GHK-Cu, SNAP-8, or the original Matrixyl (Pal-KTTKS) in a multi-peptide protocol. Do not apply to broken or actively inflamed skin.

Cycling Protocol

On Period

16 weeks

Off Period

2 weeks

Apply twice daily for 16 weeks to allow full collagen remodeling. Manufacturer clinical data shows progressive improvement through 2-6 months of consistent use. The 2-week break is optional — no receptor desensitization has been documented, and many users apply continuously. Visible results typically begin at weeks 4-8 and continue accumulating through week 16+. Effects diminish gradually over several weeks after discontinuation.

Pharmacokinetics

Half-Life

Bioavailability

Topical: <1% systemic absorption; palmitoyl conjugation enhances dermal retention across stratum corneum, epidermis, and dermis

Tmax

Not applicable (topical, non-systemic)

Data Confidence

low

Source: Estimated ~6 hours topical half-life based on Sederma product data. No formal systemic pharmacokinetic studies exist — Matrixyl 3000 is a topical cosmeceutical with minimal transdermal absorption. The palmitoyl chains enhance skin layer retention but do not promote significant systemic bioavailability.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally well-tolerated as a topical cosmeceutical. Clinical studies and the CIR safety assessment report no significant adverse effects at typical use concentrations (<10 ppm). Rare cases of mild temporary redness, tingling, or irritation at the application site may occur, particularly in individuals with sensitive skin. No systemic side effects expected due to minimal transdermal absorption. Allergic contact dermatitis is theoretically possible but has not been reported at significant rates.

Contraindications

Known allergy or hypersensitivity to palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, or palmitic acid conjugates
Active skin infections, open wounds, or severe dermatitis at intended application sites
Pregnancy or breastfeeding (no safety data available for this population)
Children under 18 (insufficient safety data)
History of contact dermatitis to cosmeceutical peptide products

Drug Interactions

Topical retinoids (tretinoin, adapalene) — may increase transient skin sensitivity when layered simultaneously; apply at separate times of day for best tolerance
High-concentration chemical peels (glycolic acid >20%, TCA peels) — compromised skin barrier after peeling may alter peptide absorption; wait 48-72 hours post-peel before resuming
Other collagen-stimulating peptides (GHK-Cu, AHK-Cu, Matrixyl) — additive collagen-boosting effects expected and generally considered beneficial in combination protocols
Topical corticosteroids — prolonged steroid use thins the dermis and may reduce the substrate available for peptide-stimulated collagen remodeling
Topical immunosuppressants (tacrolimus, pimecrolimus) — theoretical interaction with Pal-GQPR anti-inflammatory pathway; no clinical data on combination use